Hill-Rom (NYSE:HRC) issued an update on its FY 2020
Pre-Market earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 5.40 for the period, compared to the Thomson Reuters consensus estimate of $5.54.
Shares of NYSE HRC traded down $18.46 during midday trading on Friday, hitting $97.22. 2,814,498 shares of the company’s stock traded hands, compared to its average volume of 458,571. Hill-Rom has a 1 year low of $72.29 and a 1 year high of $117.68. The stock has a market capitalization of $6.47 billion, a price-to-earnings ratio of 44.60, a price-to-earnings-growth ratio of 1.14 and a beta of 0.72. The company has a debt-to-equity ratio of 1.20, a quick ratio of 1.22 and a current ratio of 1.52. The firm has a fifty day moving average of $107.95 and a 200 day moving average of $105.06.
Hill-Rom (NYSE:HRC) last released its quarterly earnings results on Friday, July 31st. The medical technology company reported $1.95 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.46 by $0.49. Hill-Rom had a net margin of 5.04% and a return on equity of 22.60%. The firm had revenue of $767.50 million during the quarter, compared to analyst estimates of $749.39 million. During the same quarter in the prior year, the firm earned $1.23 EPS. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. On average, equities analysts anticipate that Hill-Rom will post 5.4 earnings per share for the current year.
Several equities research analysts recently issued reports on HRC shares. UBS Group reduced their target price on shares of Hill-Rom from $130.00 to $125.00 and set a buy rating for the company in a report on Monday, May 4th. Barclays reissued a buy rating and issued a $125.00 target price on shares of Hill-Rom in a report on Tuesday, April 14th. Finally, Needham & Company LLC reduced their target price on shares of Hill-Rom from $131.00 to $129.00 and set a buy rating for the company in a report on Friday. Five analysts have rated the stock with a buy rating, Hill-Rom presently has a consensus rating of Buy and a consensus price target of $125.80.
In other Hill-Rom news, SVP Mary Kay Ladone sold 2,278 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $110.00, for a total value of $250,580.00. Following the completion of the transaction, the senior vice president now directly owns 8,163 shares in the company, valued at approximately $897,930. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Paul Sherwood Johnson sold 10,344 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $103.95, for a total value of $1,075,258.80. Following the completion of the transaction, the senior vice president now owns 4,999 shares of the company’s stock, valued at $519,646.05. The disclosure for this sale can be found here. Insiders sold a total of 15,747 shares of company stock valued at $1,657,089 over the last 90 days. 0.65% of the stock is currently owned by corporate insiders.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Featured Article: Dow Jones Industrial Average (DJIA)
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.